Table 4.
Control |
TS |
TS + ALA |
ALA |
||||||
---|---|---|---|---|---|---|---|---|---|
Age (days) | 7 | 21 | 7 | 21 | 7 | 21 | 7 | 21 | |
Apoptotic index (%) | 2,92 ± 1.82 | 3,01 ± 1.78 | 35,50 ± 6.11a | 30,07 ± 6.84a | 14,05 ± 1.54ab | 12,54 ± 2.43ab | 4,05 ± 0.89b | 4,25 ± 1.48b | |
Caspase-3 immunreactivity | 0,35 ± 0.15 | 0,2 ± 0.13 | 2,30 ± 0.48a | 2,1 ± 0.6a | 1,04 ± 0.39 ab | 0,81 ± 0.2 ab | 0,52 ± 0.23b | 0,4 ± 0.15 b | |
SP-A | immunreactivity | 1,43 ± 0.17 | 2,00 ± 0.24 | 0,22 ± 0.08a | 0,43 ± 0.08a | 1,03 ± 0.18 b | 1,30 ± 0.10ab | 1,13 ± 0.16b | 1,85 ± 0.19b |
mRNA level (fold change) | 1 | 1 | 0,114 ± 0.09a | 0,594 ± 0.03a | 2,495 ± 0.02ab | 2,603 ± 0.23ab | 3,173 ± 0.01ab | 3,427 ± 0.14ab | |
VEGF | immunreactivity | 1,23 ± 0.13 | 2,00 ± 0.24 | 0,43 ± 0.05a | 0,51 ± 0.11a | 0,91 ± 0.21 b | 1,45 ± 0.16 b | 1,16 ± 0.14b | 1,75 ± 0.32b |
mRNA level (fold change) | 1 | 1 | 0,131 ± 0.03a | 0,327 ± 0.12a | 2,173 ± 0.11ab | 2,561 ± 0.01ab | 5,189 ± 0.32ab | 5,971 ± 0.26ab |